BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24581579)

  • 1. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists.
    Ferrero H; García-Pascual CM; Gómez R; Delgado-Rosas F; Cauli O; Simón C; Gaytán F; Pellicer A
    Fertil Steril; 2014 May; 101(5):1411-8. PubMed ID: 24581579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
    Ferrero H; García-Pascual CM; Gaytán M; Morales C; Simón C; Gaytán F; Pellicer A; Gómez R
    Fertil Steril; 2014 Nov; 102(5):1468-1476.e1. PubMed ID: 25217874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment.
    Gómez R; Ferrero H; Delgado-Rosas F; Gaytan M; Morales C; Zimmermann RC; Simón C; Gaytan F; Pellicer A
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2484-92. PubMed ID: 21646367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonist inhibits vascular endothelial growth factor protein production and secretion in granulosa cells.
    Ferrero H; García-Pascual CM; Pellicer N; Simón C; Pellicer A; Gómez R
    Reprod Biol Endocrinol; 2015 Sep; 13():104. PubMed ID: 26377185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome.
    Neulen J; Yan Z; Raczek S; Weindel K; Keck C; Weich HA; Marmé D; Breckwoldt M
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1967-71. PubMed ID: 7775647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.
    Alvarez C; Martí-Bonmatí L; Novella-Maestre E; Sanz R; Gómez R; Fernández-Sánchez M; Simón C; Pellicer A
    J Clin Endocrinol Metab; 2007 Aug; 92(8):2931-7. PubMed ID: 17456571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor.
    Wang TH; Horng SG; Chang CL; Wu HM; Tsai YJ; Wang HS; Soong YK
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3300-8. PubMed ID: 12107240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice.
    Chuderland D; Ben-Ami I; Kaplan-Kraicer R; Grossman H; Ron-El R; Shalgi R
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E258-66. PubMed ID: 23295464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
    Soares SR; Gómez R; Simón C; García-Velasco JA; Pellicer A
    Hum Reprod Update; 2008; 14(4):321-33. PubMed ID: 18385260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiology and pathology of ovarian hyperstimulation syndrome.
    Gómez R; Soares SR; Busso C; Garcia-Velasco JA; Simón C; Pellicer A
    Semin Reprod Med; 2010 Nov; 28(6):448-57. PubMed ID: 21082502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etiology of OHSS and use of dopamine agonists.
    Soares SR
    Fertil Steril; 2012 Mar; 97(3):517-22. PubMed ID: 22265002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kisspeptin-10 inhibits OHSS by suppressing VEGF secretion.
    Zhai J; Liu J; Zhao S; Zhao H; Chen ZJ; Du Y; Li W
    Reproduction; 2017 Oct; 154(4):355-362. PubMed ID: 28676533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model.
    Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA
    Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways.
    Chen SU; Chou CH; Lin CW; Lee H; Wu JC; Lu HF; Chen CD; Yang YS
    Hum Reprod; 2010 Mar; 25(3):757-67. PubMed ID: 20008399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preliminary study on the role of vascular endothelial growth factor in pathogenesis of ovarian hyperstimulation syndrome].
    Zhou C; Yu C; Zhuang G
    Zhonghua Fu Chan Ke Za Zhi; 2001 Nov; 36(11):654-6. PubMed ID: 11930688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome.
    Scotti L; Abramovich D; Pascuali N; Irusta G; Meresman G; Tesone M; Parborell F
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():392-401. PubMed ID: 25151950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.